Literature DB >> 10367554

Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades.

M L Bocca1, F Le Doze, O Etard, M Pottier, J L'Hoste, P Denise.   

Abstract

RATIONALE: Studies report contradictory results concerning the residual effects of zolpidem and zopiclone. Moreover, residual effects of these compounds on healthy subjects have not yet been simultaneously assessed.
OBJECTIVE: The present study with healthy subjects investigated the residual effects of zolpidem 10 mg and zopiclone 7.5 mg on driving performance and on ocular saccade and compared them to those under flunitrazepam 1 mg and placebo.
METHODS: The study involved 16 subjects divided into two groups, a 9:00 a.m. group and a 11:00 a.m. group, in a balanced, double-blind, cross-over design.
RESULTS: In the 9:00 a.m. group, zolpidem had no residual effects while zopiclone and flunitrazepam both impaired driving performance (P < 0.001 for both) and increased saccadic latency (P < 0.005; P = 0.052, respectively). Zopiclone impaired driving performance 5 times less than did flunitrazepam. In the 11:00 a.m. group, zolpidem and zopiclone had no residual effects, while flunitrazepam increased saccadic latency (P = 0.065) but did not impair driving performance.
CONCLUSIONS: Zopiclone and flunitrazepam had residual effects in the first part of the morning, whereas zolpidem had no residual effects. The hierarchical character of the effects of the molecules differed according to the test administered. This is probably linked more to drug-induced specific alterations than to different sensitivities of the tests.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367554     DOI: 10.1007/s002130050961

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone.

Authors:  Arthur A Simen; Cynthia Gargano; Jang-Ho Cha; Melissa Drexel; An Bautmans; Ingeborg Heirman; Tine Laethem; Thomas Hochadel; Lien Gheyle; Kim Bleys; Chan Beals; Aubrey Stoch; Gary G Kay; Arie Struyk
Journal:  Ther Adv Drug Saf       Date:  2015-06

2.  Degradation of zopiclone during storage of spiked and authentic whole blood and matching dried blood spots.

Authors:  Ricarda Jantos; Annemiek Vermeeren; Danica Sabljic; Johannes G Ramaekers; Gisela Skopp
Journal:  Int J Legal Med       Date:  2012-04-25       Impact factor: 2.686

3.  Impaired driving performance associated with effect of time duration in patients with primary insomnia.

Authors:  Joy Perrier; Françoise Bertran; Sullivan Marie; Colette Couque; Jan Bulla; Pierre Denise; Marie-Laure Bocca
Journal:  Sleep       Date:  2014-09-01       Impact factor: 5.849

Review 4.  Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.

Authors:  K J Holm; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 5.  Zolpidem: a review of its use in the management of insomnia.

Authors:  Tracy Swainston Harrison; Gillian M Keating
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects.

Authors:  Marie-Laure Bocca; Sullivan Marie; Véronique Lelong-Boulouard; Françoise Bertran; Colette Couque; Tsellina Desfemmes; Catherine Berthelon; Jean-Noel Amato; Michèle Moessinger; Magalie Paillet-Loilier; Antoine Coquerel; Pierre Denise
Journal:  Psychopharmacology (Berl)       Date:  2010-11-18       Impact factor: 4.530

Review 7.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29

Review 8.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study.

Authors:  Mohamed Meskali; Catherine Berthelon; Sullivan Marie; Pierre Denise; Marie-Laure Bocca
Journal:  Psychopharmacology (Berl)       Date:  2009-10-02       Impact factor: 4.530

Review 10.  Impact of psychotropic medications on simulated driving: a critical review.

Authors:  Mark J Rapoport; Melanie C Baniña
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.